Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

ImmunityBio stock jumps after strong trial updates in bladder cancer and lymphoma, with enrollment ahead of schedule and FDA ...

ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ: Culver City, California Friday, January 16, 2026, 15:00 Hrs [IST ...

The QUILT-2.005 trial is a randomized registrational study designed to evaluate the effectiveness of ANKTIVA® combined with BCG in BCG-naïve patients. As of January 2026, enrollment has surpassed 85%, ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...